Percutaneous Transluminal Angioplasty (PTA) — NCD 201 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 201, the National Coverage Determination governing Medicare coverage of Percutaneous Transluminal Angioplasty (PTA), effective March 7, 2026. Here's what changes for billing teams.

CMS updated NCD 201 to reflect evolving coverage indications for PTA — a balloon catheter procedure used to dilate narrowed or occluded blood vessels — across peripheral, renal, coronary, and carotid artery applications. This modification carries high financial exposure for vascular surgery, interventional radiology, and cardiology billing teams. The policy does not list specific CPT or HCPCS codes in this version, which creates documentation and charge capture complexity you need to address before March 7, 2026.

CMS Percutaneous Transluminal Angioplasty Coverage Criteria and Medical Necessity Requirements 2026

The core question every billing team should be asking right now: does your documentation map cleanly to the medical necessity criteria CMS has laid out in NCD 201? This is where most claim denials will originate.

Under the updated coverage policy, PTA is a nationally covered Medicare benefit under two benefit categories: Inpatient Hospital Services and Physicians' Services. CMS identifies several distinct covered indications, and each one carries its own documentation requirements. Getting the indication wrong — or leaving the record thin — is how you trigger a denial on an otherwise billable procedure.

Atherosclerotic obstructive lesions remain the anchor of this coverage policy. CMS covers PTA for lesions in the lower extremities (iliac, femoral, and popliteal arteries) and upper extremities (innominate, subclavian, axillary, and brachial arteries). One thing to note explicitly: upper extremity coverage does not extend to head or neck vessels. If your documentation references upper extremity vessels without specifying the covered arteries, expect scrutiny.

For single coronary artery lesions, CMS requires three conditions to be documented simultaneously: angina refractory to optimal medical management, objective evidence of myocardial ischemia, and lesions that are anatomically amenable to angioplasty. The likely alternative must be coronary bypass surgery. If you can't document all three, the claim is not defensible under this NCD.

Renal artery PTA coverage requires documented inadequate response to medical management of symptoms, and surgery must be the likely alternative. CMS is explicit on this point: renal artery PTA is an alternative to surgery, not an add-on to medical management. That's a meaningful distinction for reimbursement purposes. If the record reads like PTA was piled on top of ongoing medical therapy with no clear indication that surgery was otherwise coming, the claim is exposed.

PTA of arteriovenous dialysis fistulas and grafts is covered regardless of whether the approach is venous or arterial. For nephrology and dialysis billing teams, this is a straightforward covered indication — but documentation of the approach still matters for accurate procedure coding.

The most complex and high-stakes section of NCD 201 involves carotid artery PTA. CMS has built a layered framework here across four distinct coverage categories, and the criteria are tighter than most billing teams realize.

Effective October 11, 2023 — and carried forward under this 2026 modification — CMS covers PTA of the carotid artery concurrent with stenting when an FDA-approved carotid stent and an FDA-approved or cleared embolic protection device are used. But coverage is conditional on stenosis thresholds:

For both symptomatic and asymptomatic patients, CMS mandates a specific diagnostic and assessment workflow. First-line evaluation must use duplex ultrasound. Computed tomography angiography (CTA) or magnetic resonance angiography (MRA) must be used to confirm the degree of stenosis, unless contraindicated. A neurological assessment by a neurologist or an NIHSS-certified health professional must occur both before and after carotid artery stenting (CAS). Every one of those steps needs to be in the record before you submit a claim.

The earlier carotid coverage pathways — FDA-approved Category B IDE clinical trials (effective July 1, 2001) and FDA-approved post-approval studies (effective October 12, 2004) — remain in the coverage policy as well. If you're billing carotid PTA under either of those pathways, you're operating in a research or post-approval study context, and your documentation requirements are governed by those specific FDA-approved protocols. Don't conflate those pathways with the 2023 general coverage expansion.

CMS Percutaneous Transluminal Angioplasty Exclusions and Non-Covered Indications

PTA of the carotid artery outside of the three coverage frameworks described above is not covered under NCD 201. Standalone carotid PTA — performed without concurrent stent placement, or without an FDA-approved carotid stent and embolic protection device — does not meet medical necessity under this policy.

The policy also draws a hard line on upper extremity coverage: head and neck vessels are explicitly excluded. If your operators are treating subclavian steal syndrome or similar conditions affecting the proximal great vessels, confirm the specific anatomy maps to the covered vessel list before billing.

Carotid artery PTA that doesn't meet the stenosis thresholds (symptomatic <50% or asymptomatic <70%) is outside coverage criteria. Document the stenosis percentage clearly — not just a clinical description of "significant stenosis." A claim without a quantified stenosis measurement is a claim that can't be defended on audit.

Coverage Indications at a Glance

CMS Percutaneous Transluminal Angioplasty Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Percutaneous Transluminal Angioplasty Under NCD 201

NCD 201 as issued in this version does not list specific CPT, HCPCS Level II, or ICD-10-CM diagnosis codes. This is a meaningful gap. PTA spans a wide range of procedure codes depending on vessel location, approach, and whether stenting is concurrent — and without CMS publishing an explicit code list in this NCD, your billing team needs to do the mapping work internally.

Cross-reference your current charge capture against the covered indications in this policy. For carotid artery procedures, device coding (stent and embolic protection) must align with the FDA-approval requirements in the coverage criteria. If your compliance officer or billing consultant hasn't reviewed your PTA code set against NCD 201 recently, that review needs to happen before March 7, 2026.

Check the CMS Medicare Coverage Database directly for any associated Local Coverage Determinations (LCDs) from your MAC that may supply the code-level specificity this NCD lacks.